. Author manuscript; available in PMC: 2025 Jan 1.

Published in final edited form as: Arterioscler Thromb Vasc Biol. 2023 Nov 21;44(1):24–47. doi: 10.1161/ATVBAHA.123.320138

Table 8:

Population studies assessing the association of femoral plaque with major adverse cardiovascular events and cardiovascular death

Study [ref]	Country, Year of publication	Population (% men, mean age)	Follow-up (years)	Outcome (n=)	Measurement	Adjusted HR (95% CI)^*	Ethnicity and/or other comments
CHU Rangueil Toulouse²⁵	France 2009	2561 (62%, 51.6y)	6	Coronary Events (94)	Femoral Plaque	2.39 [1.54–3.56]
MONICA¹⁰⁵	Germany 2006	1325 (51%, 47.9y)	13	MI (58) CVD (189)	Plaque score (0–4) assessed at carotid and femoral arteries	Per 1 score increase MI: 1.20 (0.97, 1.50) CVD: 1.44 (1.18, 1.75)
Cyprus Atherosclerosis Study¹⁰²	Cyprus 2022	985 (45%, 58.1y)	13	ASCVD (154)	Number of femoral arteries with plaque	1: 1.77 [1.03–3.05] 2: 4.25 [2.61–6.91]
CUiiDARTE¹⁰⁸	Uruguay 2020	581 (64%, 51.4y)	10	CVD (20)	Presence or absence of plaque	1.114 1.95–1.22]^*	HR estimated from AUC ratio

CHU: Centre Hopitalier Universitaire, MI myocardial infarction

MONICA: Monitoring of trends and determinants of cardiovascular disease

MI: myocardial infarction, CVD: cardiovascular death, ASCVD: atherosclerotic cardiovascular death.

approximate, derived from AUC ratios